Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease.
Nilsson K, Andersson E, Persson S, Karlsdotter K, Skogsberg J, Gustavsson S, Jendle J, Steen Carlsson K. Nilsson K, et al. Among authors: karlsdotter k. Diabetes Obes Metab. 2023 Mar;25(3):748-757. doi: 10.1111/dom.14921. Epub 2022 Dec 2. Diabetes Obes Metab. 2023. PMID: 36371543 Free PMC article.
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.
Nyström T, Toresson Grip E, Gunnarsson J, Casajust P, Karlsdotter K, Skogsberg J, Ustyugova A; EMPRISE Study Group. Nyström T, et al. Among authors: karlsdotter k. Diabetes Obes Metab. 2023 Jan;25(1):261-271. doi: 10.1111/dom.14870. Epub 2022 Oct 10. Diabetes Obes Metab. 2023. PMID: 36097728 Free PMC article.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.
Langslet G, Nyström T, Vistisen D, Carstensen B, Grip ET, Casajust P, Tskhvarashvili G, Hoti F, Klement R, Karlsdotter K, Tuovinen M, Ofstad AP, Lajer M, Shay C, Koeneman L, Farsani SF, Niskanen L, Halvorsen S. Langslet G, et al. Among authors: karlsdotter k. J Diabetes Res. 2024 Oct 12;2024:6142211. doi: 10.1155/2024/6142211. eCollection 2024. J Diabetes Res. 2024. PMID: 39430801 Free PMC article.
11 results